



ELSEVIER

Contents lists available at [ScienceDirect](#)

Lung Cancer

journal homepage: www.elsevier.com/locate/lungcan



Corrigendum

Corrigendum to “Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in *ALK*-positive non-small-cell lung cancer” [Lung Cancer 121 (July) (2018) Pages 37–40]



Makoto Nishio^{a,*}, Kazuhiko Nakagawa^b, Tetsuya Mitsudomi^c, Nobuyuki Yamamoto^d, Tomohiro Tanaka^e, Hiroshi Kuriki^e, Ali Zeaiter^f, Tomohide Tamura^g

^a Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo 135-8550, Japan

^b Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan

^c Department of Surgery, Division of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan

^d Third Department of Internal Medicine, Wakayama Medical University, Kimiidera, Wakayama 641-8509, Japan

^e Clinical Science & Strategy Department, Chugai Pharmaceutical Co. Ltd, Chuo-ku, Tokyo 103-8324, Japan

^f F. Hoffmann-La Roche Ltd, Basel, Switzerland

^g Thoracic Center, St. Luke's International Hospital, Chuo-ku, Tokyo 104-8560 Japan

The authors regret an error in Figure 1, whereby parts B and C of the figure should be reversed. The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.lungcan.2018.04.015>

* Corresponding author.

E-mail address: mnishio@jfc.or.jp (M. Nishio).

<https://doi.org/10.1016/j.lungcan.2019.04.012>